Effects of Chitosan with Three Molecular Weights on Liver Fibrosis Induced by Carbon Tetrachloride in Mice

Minshu Du,Yalu Wang,Yalan Cao,Rui Zeng,Xia You,Luan Shu,Yiping Huang,Bin Chen,Zhenhai Zhang,Zhentao An,Jing Wang
DOI: https://doi.org/10.2139/ssrn.4354814
2023-01-01
SSRN Electronic Journal
Abstract:Liver fibrosis, a chronic liver disease characterized by excessive extracellular matrix deposition, still lacks effective treatment strategies. Chitosan has been proven to have a certain therapeutic effect on carbon tetrachloride (CCl4)-induced liver fibrosis. This study aimed to use chitosan with three different molecular weights (1, 50, and 100 kDa) to treat CCl4-induced liver fibrosis in mice to explore the effect of the molecular weight on the efficacy of chitosan and determine its possible mechanism. Cellular experiments showed that chitosan was non-cytotoxic to hepatic stellate cells, indicating its safety. Animal experiments showed that chitosan could reduce body weight loss, attenuate liver tissue damage, decrease the mRNA levels of α-SMA and COL I (the key indicators of liver fibrosis), and down-regulate the levels of inflammatory factors such as IL-6, IL-1β, and TIMP-1. In the group treated with 1-kDa chitosan, the level of these indicators was lower than that in the groups treated with 50- and 100- kDa chitosan, although there was no statistically significant difference. Additionally, chitosan improved the microbial composition of the intestinal tract and restored the diversity of intestinal flora in fibrotic mice. Specifically, 1-kDa chitosan was effective in increasing the abundance of Firmicutes and Bacteroidetes and decreasing the proportion of Actinobacteria and Proteobacteria in the fibrotic mice. Thus, although chitosan of all three molecular weights can improve the disease status of liver fibrosis and regulate the microbial community composition, its molecular weight has a certain impact on its efficacy.
What problem does this paper attempt to address?